Group 1: Nuclear Power Industry - The State Council approved the construction of 10 nuclear power units, indicating a positive long-term growth outlook for the nuclear power sector in China [2][4][6] - From 2022 to 2025, China has consistently approved at least 10 nuclear power units annually, with a total of 44 units under construction as of April 2025, representing a significant increase in installed capacity [3][4] - Nuclear power is recognized as a clean and stable baseload energy source, with high utilization hours and relatively stable electricity prices, which are expected to drive revenue and profit growth for related companies [4][5][6] Group 2: ASEAN Economic Cooperation - The visit of President Xi Jinping to ASEAN countries marks a significant moment for deepening cooperation in trade, investment, and industry, contributing positively to regional and global economic development [8][9] - China and ASEAN are focusing on high-end manufacturing, mineral resource development, infrastructure cooperation, and agricultural consumption, aiming for mutual benefits and deeper integration of industrial chains [10][9] - The cooperation framework includes enhancing policy coordination, leveraging complementary advantages in technology and market, and improving trade and investment facilitation to stimulate regional growth [10][9] Group 3: Precious Metals Market - Recent signals from the U.S. government regarding easing trade tensions with China have led to a temporary decline in gold prices, but medium-term prospects for gold prices remain bullish due to ongoing geopolitical risks and potential economic downturns in the U.S. [13][15] - Global gold ETF holdings and central bank purchases, particularly from emerging markets, indicate significant room for further accumulation of gold, supporting price increases [15][13] - The copper and aluminum sectors are expected to rebound due to favorable macroeconomic policies and a shift in market sentiment following the easing of trade tensions [15][16] Group 4: Agricultural Sector - He Feng Co. - He Feng Co. reported a significant turnaround in profitability for 2024, with a net profit of 3.42 billion yuan, compared to a loss in the previous year, driven by cost reduction and efficiency improvements [18][19] - The company’s feed business faced challenges with a decline in sales volume and price, but the meat and poultry segments showed resilience and growth potential [19][20] - The company plans to achieve over 10% growth in feed sales in 2025, focusing on strategic transformations across product, channel, and management aspects [19][22] Group 5: Medical Devices - Yuyue Medical - Yuyue Medical's revenue for 2024 decreased by 5.09%, but the company is focusing on strategic investments to accelerate international expansion, particularly in the blood glucose management sector [24][25] - The Continuous Glucose Monitoring (CGM) technology is identified as a key growth driver, with new products expected to significantly increase market penetration [27][29] - The company has made a strategic investment in Inogen to enhance its presence in the U.S. and European markets, indicating a commitment to long-term growth and shareholder returns [28][29]

Core Viewpoint - The company reported a revenue of 28.767 billion yuan for 2024, a year-on-year decrease of 13.85%, while the net profit attributable to shareholders was 346 million yuan, an increase of 115.91% [1] Group 1: Financial Performance - In Q4 2024, the company achieved a revenue of 8.625 billion yuan, down 8.81% year-on-year but up 22.39% quarter-on-quarter [1] - The company's feed business revenue for 2024 was 19.1 billion yuan, a year-on-year decline of 20%, primarily due to falling feed prices and slight volume decreases [2] - The total sales volume of feed for the year was 5.41 million tons, down 7.6% year-on-year, with pig feed sales at 4.28 million tons, down 8.2% [2] Group 2: Business Segments - The pig farming segment generated a revenue of 6.28 billion yuan in 2024, a year-on-year increase of 10%, with a gross margin of 19.8%, significantly improved from -27.9% in 2023 [2] - The company plans to sell 6.4 million pigs in 2024, a year-on-year increase of 5.8%, with 3.59 million from the controlling company and 2.81 million from joint ventures [2] Group 3: Research and Development - The company has obtained 20 biosafety certificates for genetically modified organisms (15 for corn and 5 for soybeans) as of the end of 2024, with 15 new varieties approved this year [3] - The R&D expenditure for 2024 was 675 million yuan, with an R&D expense ratio of 2.3%, an increase of 0.11 percentage points year-on-year [3] Group 4: Profit Forecast and Valuation - The profit forecast for 2025 has been adjusted down to 730 million yuan, a decrease of 34%, and for 2026 to 500 million yuan, a decrease of 69% [4] - The target price for the company is set at 5.12 yuan, down from the previous 5.56 yuan, maintaining a "buy" rating [4]

Investment Rating - The report maintains an "Accumulate" rating for the company with a target price of 10.77 RMB [7][8]. Core Views - The company achieved a revenue of 103.06 billion RMB in 2024, a year-on-year decrease of 27.27%, while the net profit attributable to shareholders increased by 90.05% to 474 million RMB [1][2]. - The focus on core business operations has led to significant operational optimization, with expectations for continued cost reduction and improved financial stability [1][3]. - The company’s pig farming business has shown a substantial reduction in losses due to rising pig prices and cost optimization, while the feed business remains a stable profit contributor [2][3]. Summary by Sections Financial Performance - In 2024, the feed segment generated 68.7 billion RMB in revenue, down 15% year-on-year, while the pig farming segment saw a revenue increase of 43% to 30.4 billion RMB [2]. - The average weaning cost per pig decreased by 90 RMB to 290 RMB, and the average survival rate for fattening pigs improved to 92% [3]. Profit Forecast and Valuation - The report adjusts the profit forecast for 2025 and 2026, predicting net profits of 1.35 billion RMB and 440 million RMB respectively, with a new forecast for 2027 introduced [4]. - The target price of 10.77 RMB corresponds to a price-to-book ratio of 1.89 for 2025, reflecting the company's improving financial condition and operational metrics [4][8].

一、主要会计数据和财务指标 前十大流通股东累计持有： 53484.26万股，累计占流通股比： 76.5%，较上期变化： 45310.08万股。 | 名称 持有数量(万股) | | 占总股本比例 | 增减情况(万 | | --- | --- | --- | --- | | | | (%) | 股) | | 湛江市对虾饲料有限公司 | 26461.20 | 37.85 | 新进 | | 香港煌达实业有限公司 | 16410.60 | 23.47 | 新进 | | 湛江承泽投资中心(有限合伙) | 5239.20 | 7.49 | 新进 | | 上海景商投资管理有限公司-景商鑫誉1号私募证券投 资基金 | 1291.57 | 1.85 | -1698.41 | | 广东粤海饲料（001313）集团股份有限公司回购专用 | | | | | 证券账户 | 1060.01 | 1.52 | 7.50 | | 东莞中科中广创业投资有限公司 | 808.50 | 1.16 | -106.00 | | 华夏行业景气混合 | 642.43 | 0.92 | 新进 | | 陈乐仪 | 532.56 | 0.76 | 185.24 ...

Core Insights - The report highlights the performance of the Shanghai Composite Index and the ChiNext Index over the past year, with the Shanghai Composite Index showing a 32% increase and the ChiNext Index a 48% increase [1][2] - The report provides a detailed analysis of industry performance, indicating that the banking sector led with a 0.976% increase, while the real estate sector faced a significant decline of -3.665% [3][4] Industry Analysis - The report discusses the recent merger and acquisition policies in Guangzhou, focusing on the "12218" industrial merger opportunities, which aim to enhance industrial development [7][8] - It notes that the restructuring index fell by 5.68%, underperforming compared to the Shanghai Composite Index and the CSI 300, indicating a challenging environment for mergers and acquisitions [7] - The report identifies key merger cases, such as the acquisition of New Wave Media by Focus Media, which aims to restructure the advertising landscape [9] Company Updates - Camel Group (骆驼股份) reported a stable main business with a 10.7% year-on-year increase in revenue for 2024, and a significant 51.9% increase in net profit for Q1 2025 [28][29] - BYD (比亚迪) achieved a remarkable 100.4% year-on-year increase in net profit for Q1 2025, driven by a 59.8% increase in new energy vehicle sales [32][33] - Xiangyu Medical (翔宇医疗) faced a challenging 2024 with a 54.68% decline in net profit, but is expected to see gradual improvement in performance [36][37] Market Trends - The chemical industry is experiencing a rise in refrigerant prices due to strong global demand, with significant increases in production rates projected for the upcoming months [13][14] - The automotive sector is witnessing a surge in smart vehicle technology, with major players showcasing new models at the Shanghai Auto Show, indicating a trend towards increased automation and intelligence in vehicles [19][20] - The media industry is focusing on high-growth areas such as social media expansion and AI applications, with companies like Red Star Technology reporting substantial revenue growth [23][25]

Investment Rating - The report maintains a "Recommended" rating for the agriculture, forestry, animal husbandry, and fishery industry [1] Core Viewpoints - The report highlights strong performance in Q1 and maintains a long-term positive outlook for the pet sector [3] - The pig price is expected to fluctuate weakly, with a long-term bearish outlook for 2025 due to increased supply [5][14] - The poultry sector may see price improvements due to tariff impacts and supply chain adjustments [6][28] - The animal health sector is poised for valuation recovery driven by improved downstream demand and expansion opportunities [7][39] - The planting sector is experiencing a significant decrease in grain imports, which may affect pricing dynamics [8][44] - The feed sector remains at a low level, with expectations of increased industry concentration [9][47] - The pet market continues to grow rapidly, with strong domestic brand performance [10][52] Summary by Sections Pig Industry - Pig prices are expected to adjust slightly downwards, with a long-term bearish trend anticipated for 2025 due to increased production capacity [5][14] - As of April 24, the average pig price was 14.96 CNY/kg, with a slight weekly increase [14] Poultry Industry - The poultry sector may benefit from tariff impacts, with a potential price increase due to supply chain disruptions [6][28] - The industry is expected to stabilize at low production levels, leading to stable profitability [6][29] Animal Health - The animal health sector is seeing improved performance, with significant revenue growth reported by leading companies [7][39] - The prices of key raw materials are rising, which may enhance the performance of related companies [7][39] Planting Sector - A notable decline in grain imports was recorded in March, with a 73.5% year-on-year decrease [8][44] - The prices of major grains have shown some recovery, with corn priced at 2220 CNY/ton as of April 25 [8][44] Feed Industry - Feed prices are currently low, with a slight decrease in the price of pig feed [9][47] - The industry is expected to see increased concentration, with recommendations for leading companies [9][49] Pet Industry - The pet market in China reached a scale of 300.2 billion CNY in 2024, with a year-on-year growth of 7.5% [10][52] - Domestic brands are rapidly gaining market share, with significant growth reported for leading pet food brands [10][56]

Core Viewpoint - TianKang Biological has reported a significant turnaround in its financial performance for 2024, achieving a net profit of 605 million yuan, compared to a loss in the previous year, indicating a successful V-shaped recovery in its operations [1][2]. Group 1: Financial Performance - The company achieved total operating revenue of 17.176 billion yuan, with a notable increase in profit margins across its three main business segments: pig farming, feed, and veterinary medicine [1]. - The pig farming segment generated revenue of 6.157 billion yuan, reflecting an 11.11% increase year-on-year, with a gross margin of 14.61%, up by 28.43% from the previous year [2]. Group 2: Business Structure and Capabilities - TianKang Biological is recognized as a key agricultural enterprise in China, with a complete industry chain covering breeding, feed management, veterinary medicine, and meat processing [1]. - The company operates over 30 feed production facilities nationwide and ranks among the top 20 in the national feed industry [1]. Group 3: Research and Development - The company has invested over 15% of its biopharmaceutical sales revenue into R&D, establishing research centers in Xinjiang and Jiangsu [2]. - It has developed China's first genetically engineered inactivated vaccine for swine fever, providing significant support for disease control in pigs [2]. Group 4: Future Outlook - TianKang Biological aims to achieve a total revenue of 21 billion yuan by 2025, with specific targets for feed production, animal vaccines, and pig output [3]. - The company plans to enhance its service offerings to farmers, focusing on key areas such as feed, breeding, and veterinary services to improve farming efficiency [3]. Group 5: Shareholder Returns - The company has proposed a cash dividend of 2.20 yuan per 10 shares, translating to an approximate dividend yield of 3.52% based on the closing price on April 28 [3].

农林牧渔/饲料 禾丰股份（603609.SH） 白鸡屠宰量稳步上行，生猪业务回暖贡献利润 2025 年 04 月 28 日 投资评级：买入（维持） | 日期 | 2025/4/28 | | --- | --- | | 当前股价(元) | 8.26 | | 一年最高最低(元) | 9.38/5.96 | | 总市值(亿元) | 75.95 | | 流通市值(亿元) | 75.95 | | 总股本(亿股) | 9.19 | | 流通股本(亿股) | 9.19 | | 近 3 个月换手率(%) | 52.26 | 股价走势图 数据来源：聚源 -24% -12% 0% 12% 24% 36% 2024-04 2024-08 2024-12 禾丰股份 沪深300 相关研究报告 陈雪丽（分析师） 朱本伦（联系人） chenxueli@kysec.cn 证书编号：S0790520030001 zhubenlun@kysec.cn 证书编号：S0790124060020 风险提示：公司成本不及预期，猪鸡涨价不及预期，疫病风险，原料价格风险。 | 财务摘要和估值指标 | | | | | | | --- | --- | --- ...

Group 1: Future Growth Strategies - The company aims to achieve over 3 million tons of export volume by 2025 and 51.5 million tons of total sales by 2030, focusing on expanding its feed business as the core strategy [2][3] - The company is exploring light-asset pig farming and factory-style shrimp farming, which are expected to become key business areas in the future [2][3] Group 2: Financial Performance - In 2024, the company achieved a feed sales volume of 26.52 million tons, a year-on-year increase of approximately 9%, with a net profit of 4.504 billion yuan, up 64.3% [3][4] - The company's revenue for 2024 was 114.601 billion yuan, a slight decrease of 1.31% year-on-year [3][4] Group 3: Market Position and Competition - The company’s domestic feed sales volume reached 22.06 million tons, with a year-on-year growth of about 5%, while the overall industrial feed production in China declined by 2.1% [5][6] - The company is focusing on enhancing its market share in regions such as South China, East China, and North China through operational excellence and customer orientation [5][6] Group 4: Risk Management and Challenges - The company has established a strict disease prevention system in feed production to mitigate risks associated with livestock diseases [6][7] - The company is prepared for future competition in overseas markets and is gradually expanding its seedling and feed businesses internationally [6][7] Group 5: Capital Management and Shareholder Returns - The company plans to distribute cash dividends of 1.8 billion yuan in 2024, with future distributions based on actual operating conditions [7][8] - The company’s debt levels and asset-liability ratios have decreased as of the end of 2024, indicating improved financial health [7][8]

新华财经上海4月28日电随着财报披露接近尾声，公募机构正加紧对上市公司基本面进行最后验证：一 方面深度挖掘年报业绩超预期标的，另一方面提前布局一季报展现成长性的优质企业。这种密集调研行 为既反映了公募机构对财报季投资机会的重视，也预示着二季度调仓换股的序幕正在拉开。 据公募排排网统计数据显示，在上市公司年报及一季报披露进入收官阶段的关键窗口期（2025年4月21 日-4月27日），公募机构调研活动呈现爆发式增长。全市场156家公募机构参与调研，囊括了全市场 95%以上的公募机构，调研范围涵盖26个申万一级行业的244家上市公司，合计调研频次达2849次，周 度环比大增163.80%。 数据显示，上周共有178只个股获得公募机构密集调研，被调研次数均不少于5次，平均日均调研不低于 1次。通信行业中有3只个股跻身前十，分别是天孚通信、仕佳光子和新易盛，依次被调研62次、42次和 38次，其中天孚通信位列被调研次数位列榜首，仕佳光子则以66.54%的涨幅成为上周表现最为突出的 公募调研股。此外，农林牧渔与电子行业各有2只个股进入调研热度前十。 | 上周公募调研次数前十个股 | 申万一级行业 | 被调研次数(次) | ...